Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Brigham Buhler, a MAHA influencer and biotech entrepreneur, has Robert F. Kennedy’s ear. But will RFK listen to his call to ...

Alkem Laboratories Ltd.'s proposed copies of two extended-release Xeljanz dosages infringe a patent for Pfizer Inc.'s once-blockbuster arthritis drug, a federal lawsuit said. Pfizer alleged Alkem’s ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch this year that are expected to make blockbuster sales by 2023. JAK1 inhibitor upadacitinib for ...

The global artificial intelligence in drug discovery market is experiencing unprecedented growth, driven by technological advancements, increasing R&D costs, and the need for faster, more efficient ...